Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease

Abstract: Bronchiolitis obliterans syndrome (BOS) is a severe form of chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic cell transplant (HCT), with a 5-year survival rate of 40%. Currently, there is no curative therapy for BOS. Preclinical data suggest that pirfenidone, an...

Cijeli opis

Bibliografski detalji

Glavni autori:	Husham Sharifi, Carson Tyler Moss, Zayan Musa, Alexander Bell, Christian O’Donnell, Carlos Hernandez Borges, Efthymia Iliana Matthaiou, Laura Johnston, Craig J. Galban, Ajay Sheshadri, Gregory Yanik, Guang-Shing Cheng, Joe L. Hsu
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-10-01
Serija:	Blood Advances
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2473952925003519
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!